Scarica l'app Stockscreener
140.98
0.31%
0.43
Dopo l'orario di chiusura:
141.55
0.57
+0.40%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Biogen Inc Borsa (BIIB) Ultime notizie
Sage lawsuit enforces standstill as board evaluates Biogen offer - BioWorld Online
BIOGEN TO REPORT FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS FEBRUARY 12, 2025 - Biogen | Investor Relations
Looking At Biogen's Recent Unusual Options Activity - Benzinga
Sage sues partner Biogen after unsolicited takeover offer - PharmaLive
Alzheimer's Drugs Market Growth: AbbVie, Amgen, and Biogen Pioneering New Therapeutic Solutions - openPR
Guardian Investment Management Sells 2,865 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Sax Wealth Advisors LLC Invests $337,000 in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Avanza Fonder AB Makes New Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Announces New Chief Accounting Officer Appointment - MSN
Sage sues Biogen after unsolicited takeover bid - pharmaphorum
BRIEF—Biogen sued by Sage after buyout offer - The Pharma Letter
Wedge Capital Management L L P NC Acquires 26,530 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen, Sarepta Quick Drug Approvals Show FDA Gaps, Report Says - MSN
Biogen (NASDAQ:BIIB) Sets New 52-Week LowHere's What Happened - MarketBeat
Biogen Beats Humana's RICO Suit Over MS Drug Scheme on Appeal - Bloomberg Law
Sage sues Biogen in wake of $469M buyout offer: report (BIIB:NASDAQ) - Seeking Alpha
Biogen, Eisai say injectable Alzheimer’s therapy granted FDA review - MSN
Alzheimer’s drugs eyed as next big obesity-like opportunity - The Keene Sentinel
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt - Benzinga
Biogen Sued by Neuroscience Company Sage After Buyout Offer (1) - Bloomberg Law
Biogen's Quarterly Earnings Preview: What You Need to Know - Nasdaq
Biogen's Quarterly Earnings Preview: What You Need To Know - Barchart
Biogen Inc. Announces Executive Changes Effective March 1, 2025 -January 15, 2025 at 08:00 am EST - Marketscreener.com
Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates - Yahoo Finance
The Escalator: Lykos Therapeutics, Biogen, CMI Media Group and more - MM+M Online
Czech National Bank Acquires 1,923 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Wedmont Private Capital Has $546,000 Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen stock at lowest level since February 2013 following J.P. Morgan presentation - MSN
Amyotrophic Lateral Sclerosis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Treatment Outlook | Biogen, GSK, Helixmith, Sanofi, Denali Therapeutics, Ionis Pharma, Brainstorm Cell - The Globe and Mail
Biogen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Short Interest in Biogen Inc. (NASDAQ:BIIB) Increases By 42.6% - MarketBeat
Biogen stock stays strong with Outperform rating as Oppenheimer highlights disciplined growth strategy - Investing.com India
Biogen appoints new Chief Accounting Officer - Investing.com
OIG raises concerns about accelerated approval deviations - BioWorld Online
At JPM, Biogen CEO tries to take down the deal temperature - BioPharma Dive
Biogen Inc. (BIIB) Appoints New Chief Accounting Officer - GuruFocus.com
Biogen Says It's 'Doubling Down' on Alzheimer's Disease at JPM - Precision Medicine Online
Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders - Seeking Alpha
Under Pressure to Deal, Biogen Executives Deflect Urgency at JPM25 - BioSpace
JPM25 day two: Roche, Amgen, Merck, Lilly, and Biogen - PharmaLive
Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More - BioSpace
Inspector General Questions FDA’s Accelerated Approval for Biogen, Sarepta Drugs - BioSpace
Biogen CEO Discusses Strategy to Rely on New Product Launches for GrowthNews and Statistics - IndexBox, Inc.
JPM25 Day Two: Roche, Amgen, Merck, Lilly and Biogen - BioSpace
Biogen/Eisai announce FDA BLA acceptance for injectable Alzheimer’s drug - PMLiVE
Biogen lays out three FDA decisions that could ramp up Alzheimer's drug launch - The Business Journals
Biogen CEO targets faster dementia treatment launch with new subcutaneous Leqembi optionCHOSUNBIZ - 조선비즈
Alport Syndrome Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Eloxx Pharmac, Biogen, River 3 Renal Corp, Travere Therapeutics, Chinook Therapeutics - Barchart
Biogen Looks Ahead With Confidence As New Products Take Charge - Finimize
JPM25: Biogen 'doubling down' on Alzheimer's in long bet - FirstWord Pharma
Biogen CEO sees no burning need for more acquisitions - Reuters
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Sarepta, Biogen drugs with accelerated approval under fire in FDA report - Seeking Alpha
JPM25, Day 2: Biogen ready to stand its ground in Alzheimer's showdown, CEO says - FiercePharma
Biogen, Sarepta Quick Drug Approvals Show FDA Gaps, Report Says | Company Business News - Mint
Biogen (NASDAQ:BIIB) Reaches New 12-Month LowHere's What Happened - MarketBeat
Biogen stock touches 52-week low at $144.96 amid challenges - Investing.com
BRIEF—FDA accepts BLA for subcutaneous Leqembi - The Pharma Letter
This Biogen Insider Increased Their Holding In The Last Year - Simply Wall St
1.22%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):